Table 3.
Baseline characteristics in CAD patients with or without MACE
| Characteristics |
MACE |
p | |
|---|---|---|---|
| Present, n = 102 | Absent, n = 415 | ||
| Age (yrs) |
64.8 ± 12.1 |
63.1 ± 11.2 |
0.168 |
| Male (%) |
86.3 |
81.4 |
0.251 |
| Smokers (%) |
30.4 |
39.3 |
0.155 |
| Hypertension (%) |
66.7.00 |
56.70 |
0.105 |
| Diabetes mellitus (%) |
30.4 |
21.9 |
0.071 |
| History of AMI (%) |
35.5 |
36.8 |
0.782 |
| History of stroke |
4.9 |
4.6 |
0.798 |
| Previous PCI |
22.5 |
15.7 |
0.097 |
| SBP (mmHg) |
134.9 ± 23.2 |
129.7 ± 20.4 |
0.022 |
| Body mass index (kg/m2) |
20.8 ± 7.6 |
21.4 ± 8.2 |
0.751 |
| Total cholesterol (mmol/L) |
4.39 ± 1.27 |
4.44 ± 1.22 |
0.681 |
| Triglycerides (mmol/L) |
1.17 (0.87, 1.69) |
1.30 (0.98, 1.81) |
0.306 |
| LDL-C (mmol/L) |
2.71 ± 1.04 |
2.75 ± 0.99 |
0.729 |
| HDL-C (mmol/L) |
1.08 ± 0.29 |
1.10 ± 0.30 |
0.627 |
| Lp(a) (mg/dl) |
36.3 (12.8, 56.4) |
22.4 (10.5, 45.7) |
0.012 |
| hs-CRP (mg/l) |
3.34 (1.48, 6.80) |
3.33 (1.35, 10.80) |
0.200 |
| eGFR (ml/min/1.73 m2) |
92.9 ± 34.1 |
97.5 ± 33.7 |
0.228 |
| HbAc1 (%) |
6.52 ± 0.98 |
6.41 ± 1.21 |
0.496 |
| LVEF (%) |
56.0 ± 13.7 |
59.8 ± 10.9 |
0.003 |
| Coronary type |
|
|
|
| Stable angina |
33.3 |
22.9 |
0.029 |
| Unstable angina |
28.4 |
39.5 |
0.038 |
| AMI |
38.2 |
37.6 |
0.904 |
| Number of lesion vessels |
2.34 ± 0.76 |
2.15 ± 0.81 |
0.034 |
| Three-vessel disease |
52.0 |
41.9 |
0.067 |
| Left main disease |
16.7 |
11.8 |
0.188 |
| Statins |
100 |
98.1 |
0.366 |
| β-blockers |
74.5 |
81.4 |
0.103 |
| ACE inhibitors/ARB | 81.4 | 80.7 | 0.881 |
Abbreviations: CAD coronary artery disease, MACE major adverse cardiovascular event, AMI acute myocardial infarction, SBP systolic blood pressure, ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, LVEF left ventricular ejection fraction, hs-CRP high sensitive reactive protein, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention.